26.2 C
Vientiane
Friday, August 29, 2025
spot_img
Home Blog Page 53

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

  • The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1
  • DEEs are the most severe rare epilepsies, characterized by drug-resistant seizures, frequent epileptic activity on EEG and developmental slowing or regression2
  • Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor seizure frequency in the extension study comparable to reductions seen in the Phase 1b/2a PACIFIC trial, reinforcing durability of response and validating its progression to Phase 3 trials1
  • Additional data will be presented from the audiogenic seizure model and the GAERS absence epilepsy model, investigating sudden unexpected death in epilepsy (SUDEP), and seizure reduction respectively.3,4

VALBY, Denmark, Aug. 25, 2025 /PRNewswire/ — H. Lundbeck A/S (Lundbeck) today announced that new data regarding bexicaserin, a novel treatment under investigation for seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will be presented at the 36th International Epilepsy Congress (IEC) in Lisbon, Portugal (Aug 30Sept 3).

Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide. The efficacy and safety of bexicaserin has not been established.

“Patients with DEEs represent a challenging group of rare epilepsies, with few effective approved treatment options,” said Johan Luthman, EVP and Head of Research and Development at Lundbeck. “As we are now in phase 3 trials with bexicaserin, we are optimistic about its potential. The clinical data so far suggests broad and durable anti-seizure activity across DEEs, and new preclinical data suggests modulation of the risk of sudden unexpected death in epilepsy (SUDEP). This marks a significant step forward in the potential to transform care for patients and address critical gaps in the treatment landscape.”

The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial will be presented. It was designed to evaluate the long-term (up to 52 weeks), safety, tolerability, and efficacy of bexicaserin in individuals with a DEE. During the OLE, a median reduction of 59.3% in countable motor seizure frequency was observed, with 55% of participants experiencing sustained reductions of ≥50% compared to baseline before the PACIFIC trial. Bexicaserin was well tolerated, with no new safety signals observed.

“I am encouraged by the 100% enrollment of eligible participants and the high completion rate of over 90% in the open-label extension study. Such high retention underscores the tolerability as well as the duration of effect of bexicaserin across developmental and epileptic encephalopathies,” said Ingrid E. Scheffer, Lead Investigator and Laureate Professor of Pediatric Neurology, The University of Melbourne and Austin Health.

Lundbeck will also showcase preclinical data in an audiogenic seizure model of SUDEP, the most common cause of premature death in children and adults with epilepsy.3,6 Bexicaserin significantly reduced seizures and respiratory arrest in the SUDEP model. Furthermore, preclinical data will be shared indicating the impact of bexicaserin on absence seizures, a type of seizure that is often more difficult to treat.4,7

Bexicaserin has entered late-stage clinical development through the global phase 3 program, DEEp, aimed at evaluating its safety, tolerability, and efficacy in the treatment of seizures in children and adults with DEEs. The DEEpSEA trial8 is currently recruiting participants with Dravet syndrome and the DEEpOCEAN trial9 is open to individuals with DEEs (including Lennox-Gastaut syndrome).  

Both trials are randomized, double-blind, placebo-controlled and open for enrollment across the North America, Europe, Asia, Australia and Latin America, with additional sites being activated on a rolling basis.

Lundbeck’s scientific presentations at IEC:

Long-term Safety, Tolerability, and Efficacy of Bexicaserin for the Treatment of Seizures in Participants With Developmental and Epileptic Encephalopathies: Primary Results of the 12-Month Phase 1b/2a PACIFIC Trial Open-Label Extension. Poster presentation, 31 August 2025; 13:45-15:15 WEST 1

Activation of Central 5-HT2C Receptors by Bexicaserin Modulates Seizures and Respiratory Arrest in a Mouse Model of SUDEP. Platform presentation, 31 August 2025; 14:30 – 15:00 WEST 3

Impact of Bexicaserin on Seizures and Interictal Spectral Power in the GAERS Absence Epilepsy Model. Poster presentation, 31 August 2025; 13:45-15:15 WEST 4

Seizure Reductions and Tolerability in Participants With Developmental and Epileptic Encephalopathies Newly Exposed to Bexicaserin: Interim Results From the Phase 1b/2a PACIFIC Open-Label Extension. Poster presentation, 1 September 2025; 13:45-15:15 WEST10

About Bexicaserin

Bexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risks of cardiovascular toxicity associated with nonselective serotonergic agents. Bexicaserin is being evaluated in a global Phase 3 clinical program (the DEEp Program). The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide.

About the PACIFIC trial

The PACIFIC trial was a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, efficacy, and pharmacokinetics of bexicaserin in 52 participants between the ages of 12 and 65 years old with any type of DEE (Dravet syndrome, Lennox-Gastaut syndrome and DEE other) at 34 sites across the United States and Australia. Participants who had ≥4 countable motor seizures during the 28-day baseline period, while on a stable regimen of 1 to 4 concomitant antiseizure medications were included.11

Following a 28-d baseline period, study participants initiated a dose titration over a 15-day period and subsequently continued on the highest tolerated dose throughout the maintenance period of 60 days. Eligible participants were given the opportunity to enroll in a 52-week open-label extension if they completed the 75-d RCT treatment period (titration and maintenance). The OLE duration was 52 weeks and included patients with Dravet syndrome (n=3), Lennox-Gastaut syndrome (n=20) and DEE Other (n=18), who completed the PACIFIC trial (n=41).

Contacts:
Marie Petterson
Head of Media Relations, Corp. Communication
MEEP@lundbeck.com 
+45 29 82 21 82

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com 
+45 30 83 45 01

Palle Holm Olesen
Vice President, Investor Relations
PALO@lundbeck.com 
+45 30 83 24 26

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References:

  1. Dlugos DJ, et al. Poster presentation: International Epilepsy Congress 2025.
  2. Sheffer IE, et al. Epilepsia. 2025;00:1-10
  3. Vermudez S, et al. Platform Presentation: International Epilepsy Congress 2025.
  4. Vermudez S, et al. Poster Presentation: International Epilepsy Congress 2025.
  5. American Academy of Neurology Annual Meeting 2025. Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants with Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension.
  6. Donner EJ, et al. Pediatric Neurology, 2017;70:7-15
  7. Daquin G, Bonini F. Revue Neurologique, 2024;180(4):256-270
  8. https://clinicaltrials.gov/study/NCT06660394
  9. https://clinicaltrials.gov/study/NCT06719141
  10. Ngoc Minh Le et al. Poster presentation: International Epilepsy Congress 2025
  11. Kaye R, et al. Efficacy and safety of bexicaserin (LP352) in adolescent and adult participants with developmental and epileptic encephalopathies: Results of the phase 1b/2a PACIFIC study. Presented at the Annual Meeting of the American Academy of Neurology; April 13-18, 2024

Contacts:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-to-present-new-data-on-bexicaserin-at-upcoming-congress–highlighting-long-term-impact-on-s,c4222334

The following files are available for download:

https://mb.cision.com/Main/18215/4222334/3624393.pdf

Bexicaserin IEC curtain raiser Final

 

 

 

Galan Lithium Limited: SUCCESSFUL DUE DILIGENCE COMPLETED – $20M PLACEMENT TO PROCEED

Highlights:

  • All conditions in relation to the $20 million placement to Clean Elements Fund have been satisfied.
  • Due diligence undertaken by Clean Elements Fund validates the standing of Hombre Muerto West (HMW) as a world class lithium project, offering exceptional scale and grade.
  • Galan is now fully funded to complete the construction of Phase 1 at HMW (at 4ktpa LCE) with first production of lithium chloride concentrate planned during H1 2026.

PERTH, Australia, Aug. 25, 2025 /PRNewswire/ — Galan Lithium Limited (ASX: GLN) (Galan or the Company) is pleased to announce that all conditions relating to the $20 million share placement (Placement) to the Clean Elements Fund (Clean Elements) have now been completed.

The Placement, which was undertaken at a significant premium to the prevailing share price when originally announced, was subject to certain conditions including shareholder approvals (received at a General Meeting held on Friday, 22 August 2025) as well as the satisfactory completion by Clean Elements of technical and legal due diligence in respect of the Company and HMW in Argentina. 

Clean Elements has advised that all conditions to the Placement have been satisfied. As such, the Placement will now proceed to settlement, providing Galan with the funding required for the finalisation of the HMW Phase 1 construction over the remainder of the 2025 calendar year, with first production of lithium chloride concentrate scheduled for H1 2026.

Settlement will take place in two equal tranches of $10 million.  Tranche 1 settlement will occur within the next 5 business days and Tranche 2 of the Placement will settle no later than 22 November 2025, in line with the timing set out in the relevant shareholder approval.

Managing Director, Juan Pablo Vargas de la Vega, commented: “With the support of Clean Elements, Galan now has the funding certainty to complete Phase 1 construction at HMW and is firmly on track to deliver first lithium chloride concentrate production in H1 2026.

The due diligence undertaken by Clean Elements Fund has confirmed, what we at Galan already know – HMW is an exceptional lithium project, combining substantial scale and grade with execution capability that places it among the best globally.

The team at Galan remains focussed on advancing project delivery at HMW and we look forward to creating significant long-term value for shareholders as we progress towards production.”

Clean Element’s Chairman, Ofer Amir, commented:  “We are thrilled to confirm a binding and unconditional commitment to complete both tranches of the placement—an outcome that underscores strong confidence in Galan’s strategic direction.

Our specialist lithium brine adviser highlighted that HMW is the premier lithium brine resource globally. HMW’s brine is the highest grade in Argentina with the lowest impurity profile. It also contains significantly less magnesium and calcium than the levels found in the Salar de Atacama in Chile which, when combined with HMW’s high lithium grades, gives rise to the highest lithium recoveries in the lithium brine sector to date.

This exceptional resource quality enables a low-cost, evaporation process—positioning Galan to become a high-margin, globally competitive lithium producer. In our view, Galan will not just be participating in the lithium market; it will be setting a new benchmark.”

The Galan Board has authorised this release.

For further information contact:

COMPANY

MEDIA

Juan Pablo (“JP”) Vargas de la Vega

Matt Worner

Managing Director

Vector Advisors

jp@galanlithium.com.au

mworner@vectoradvisors.au

+ 61 8 9214 2150

+61 429 522 924

 

DAHON-V – a Revolutionary Bike Tech Pushing a New Frontier in Green Mobility

BEIJING, Aug. 25, 2025 /PRNewswire/ — At the “JD Cycling Festival” in Beijing, China, the silver-gray, drop-bar folding bike DAHON P18 Ultra zipped past the finish line and claimed victory with lightning speed, challenging the industry’s perception that “portability and speed cannot coexist” for folding bikes. This decisive victory not only ignited a renewed interest in folding bikes among cycling enthusiasts but also brought DAHON’s proprietary bike tech DAHON-V into the spotlight for its speed.

Champion with DAHON P18 Ultra (center) and other medalists at the “JD Cycling Festival”
Champion with DAHON P18 Ultra (center) and other medalists at the “JD Cycling Festival”

DAHON-V Bike Tech: A revolutionary leap from the lab to track

The secret behind the championship of DAHON P18 Ultra lies in its DAHON-V technology suite, a set of bicycle design and testing technologies and methods that effectively address structural shortcomings found in most bikes and boost the speed of all types of bikes. It features patented technologies like DELTECH cable and Super Downtube that enable folding bikes to achieve performance levels comparable to that of road bikes for the first time.

Unleashing Freedom of Travel: From daily commuting to casual racing

Present on the DAHON P18, the pioneering “one-bike, dual-mode” design allows riders to fold and carry a bike easily onto subways or buses when folded, and switch to a road bike structure with the drop-bar after unfolding, perfectly addressing urban cyclists’ desire for both efficiency and style. Currently, DAHON’s folding bikes equipped with this technology are in high demand, reflecting the market’s strong desire for innovative products, above and beyond just a bike! 

DAHON P18 Ultra Folding Road Bike (Left), DELTECH cable (Upper right), Super Downtube (Lower right)
DAHON P18 Ultra Folding Road Bike (Left), DELTECH cable (Upper right), Super Downtube (Lower right)

Green Promise: Where speed meets sustainability

Guided by the “dual-carbon” goals, DAHON is evolving from a manufacturer into a technology enabler. Through its “Sharing 360” patent licensing program, DAHON forms strategic alliances with industry leaders such as Golden Wheel Group and Shenyang (SYB), sharing proprietary technologies to raise industry standards.

Speed Has No Limits; Innovation Knows No Bounds

From Magellan’s 37-month circumnavigation to the Wright brothers’ invention of the first flight for mankind, humanity’s pursuit of speed has always been about expanding the boundaries of freedom.

DAHON-V embodies that same spirit for the modern age: recalibrating mechanics using steel cables and algorithms, redefining the possibilities of folding and racing, and safeguarding sustainability with lightweight and smart design.

At this moment, DAHON is racing forward at “DAHON-V” speed into a greener tomorrow. As its gears turn to the rhythm of innovation, a new chapter of efficiency, freedom, and sustainability is being written—one that the world will witness together.

Speed has no limits, and DAHON is writing a new definition to unfold a new chapter of bike tech!

For more information, please contact marketing@dahon.com

www.dahon.com
usa.dahon.com

The 20th anniversary of the “Two Mountains Concept”: People’s Daily releases a promotional video-Bamboo Sees New Life

BEIJING, Aug. 25, 2025 /PRNewswire/ — August 15, 2025, marks the 20th anniversary of the “Two Mountains” concept. People’s Daily released a promotional video, “Bamboo Sees New Life”. The video tells the story of Yucun Village in Zhejiang Province. Twenty years ago, due to mountain quarrying, the mountains in Yucun became bare, and the streams were seriously polluted, whose water color was like soy sauce. However, now, it is like a beautiful traditional Chinese landscape painting. This documentary vividly depicts the practice of China’s rural revitalization, shows a rural sample of Chinese-style modernization, and serves as a vivid interpretation of General Secretary Xi Jinping’s famous statement that “lucid waters and lush mountains are invaluable assets”. 

 

People’s Daily releases a promotional video-Bamboo Sees New Life

Bigo Live Brings Global Creator Community Together at Turkey Mid-Year Gala


ISTANBUL, TURKEY – Media OutReach Newswire – 25 August 2025 – Bigo Live, a leading global social live-streaming platform, proudly presents its most anticipated Turkey Mid-Year Gala 2025, taking place on August 26 at the iconic Çırağan Palace Kempinski in Istanbul. Themed “Live Beyond the Screen,” the Gala celebrates the role of livestreaming in bridging cultures, empowering creators, and building meaningful connections both online and offline.

Bigo Live Brings Global Creator Community Together at Turkey Mid-Year Gala

As a key milestone in Bigo Live’s expansion across Turkey and the wider region, the event brings together over 200 top creators and business partners from across more than 15 countries and regions across Europe and Asia to honor creativity and connection. The evening will pay tribute to some of the most influential and inspiring voices on the platform through cornerstone awards, including Mid-Year GALA Family Winners, Mid-Year GALA Influencer Winners, Mid-Year GALA Agency Winners, Mid-Year GALA Creator Winners, and others. Winners will receive a specially designed trophy along with limited-edition Bigo Live merchandise and gifts in recognition of their outstanding contributions.

The Gala will also spotlight the creative diversity of Bigo Live’s global community through a vibrant mix of music, dance, and performance art. Highlights include a violin solo by Turkish artist nahidemusic, to an original vocal piece by Italian creator _kimura. Dynamic group dance performance from Commonwealth of Independent States (CIS) performers PERFECT (Bigo ID: 737040403), DIVA (Bigo ID: 7788ok), and MILA (Bigo ID: Miillamur) will bring high-energy flair to the stage, while Turkish creator BayZarif and assistant BERSSUU will offer a unique ventriloquism act blending humor and storytelling. German vocalist Nissim will add depth with a soulful performance. Traditional and contemporary Turkish dance pieces will complement the lineup, adding strong local character to this global showcase.

“The Turkey Mid-Year Gala is more than a celebration of achievement, it’s a reflection of our commitment to fostering a diverse, inclusive, and inspiring creator community,” said a Bigo Live spokesperson. “This Gala celebrates how real connections—across cultures and borders—can begin and grow through a screen.”

The Gala will also be livestreamed on Bigo Live’s official channel via the Bigo Live app, inviting a global audience to tune in and take part through real-time chat, virtual gifting, and prize opportunities. Follow Bigo Live on Instagram for updates, and join us in celebrating the transformative power of livestreaming.

Hashtag: #Bigo

The issuer is solely responsible for the content of this announcement.

Hear, Charge, Protect — Baseus Brings the Inspire Series and Fresh Innovations to IFA 2025

SHENZHEN, China, Aug. 25, 2025 /PRNewswire/ — Baseus, a global leader in consumer electronics, will debut its flagship Inspire series of audio products with Sound by Bose technology  — setting a new standard in accessible high-end sound at IFA 2025. Mark your calendar for September 5–10 and visit Baseus at Messe Berlin, Hall 4.2, Booth 147 for a firsthand look at the Inspire series and a showcase of cutting-edge innovations that redefine innovation, convenience, and intelligence.

Baseus Inspire Series
Baseus Inspire Series

Baseus’s Inspire audio series will take center stage at IFA 2025 with three distinct models: over-ear, open-ear, and in-ear. The open-ear design stands out with an industry-first Hybrid 2-Way Driver System in this form factor.

Hybrid 2-Way Driver System
Hybrid 2-Way Driver System

Baseus demonstrates how thoughtful acoustic engineering and pioneering hardware can elevate everyday audio experiences, setting a new benchmark for accessible premium sound.

Baseus Security X1 Pro
Baseus Security X1 Pro

Beyond audio, Baseus will spotlight its broader ecosystem. In smart security, the company will introduce the Security X1 Pro, the world’s first Smart AI Dual-Tracking Security Camera with 3K resolution and 300° of horizontal tracking range—showcasing how protection, power, and sound come together seamlessly within the Baseus experience.

Visitors can also expect the PicoGo II series of fast, travel-ready, and reliable power solutions—including compact high-output GaN chargers and Qi2.2-ready magnetic options that deliver speed and safety while fitting seamlessly with the latest flagship smartphones.

By bringing together advancements in sound, power, and security, Baseus aims to demonstrate at IFA 2025 how technology can be both innovative and accessible. The showcase underscores Baseus’s commitment to shaping smarter, more connected lifestyles for millions of users worldwide, while marking another milestone in the its journey from trusted accessory maker to global technology brand.

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users’ problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products – including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users’ sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:

Name: Baseus PR Team
Email: pr@baseus.com
Baseus Official Website: https://www.baseus.com/

 

AI-Powered Pet-Friendly Smart Security: Arlo Essential Indoor 2K Security Camera Offers Peace of Mind


HONG KONG SAR – Media OutReach Newswire – 25 August 2025 – Never worry about leaving your pet at home again. The Arlo Essential Indoor 2K Security Camera empowers pet owners to stay connected anytime, anywhere, with crystal-clear video, a wide field of view, night vision, and noise-canceling two-way audio. Whether you’re at work or across the globe, you can see, talk to, and comfort your furry friend with ease.

Arlo Essential Indoor 2K Security Camera
Arlo Essential Indoor 2K Security Camera

Monitor your pet 24/7 through live video, use two-way audio to guide or soothe them, and ensure their safety with real-time interaction. When you’re home, the Automated Privacy Shield, easily activated via the Arlo Secure app, protects your privacy and keeps your downtime off-camera.

Elevate your experience with an Arlo Secure subscription for cloud recording, smart notifications, and AI-powered detection. These features deliver enhanced control, sharper insights, and unmatched peace of mind for pet lovers and families.

Top Tips for Keeping Pets Safe When You’re Away:

  • Check in Regularly: Use live video to ensure your pet is safe and not getting into mischief.
  • Engage with Two-Way Audio: Comfort or redirect your pet with your voice, reinforcing commands like “stay” or “down.”
  • Stay Alert with AI Notifications: Get instant alerts for unusual activity, excessive barking, or prolonged silence to act quickly.
  • Protect Privacy: Activate the Automated Privacy Shield when you’re home to keep your pet’s (and your) downtime private.
  • Review Behavior Patterns: Access cloud recordings to spot trends or potential hazards in your pet’s routine.

With the Arlo Essential Indoor 2K Security Camera, you’re always close enough to keep your pet safe, reassured, and loved—no matter where life takes you.

Hashtag: #Arlo

The issuer is solely responsible for the content of this announcement.

About Arlo Technologies, Inc.

Arlo is an award-winning, industry leader that is transforming the ways in which people can protect everything that matters to them with advanced home, business, and personal security solutions. Arlo’s deep expertise in AI- and CV-powered analytics, cloud services, user experience and product design, and innovative wireless and RF connectivity enables the delivery of a seamless, smart security experience for Arlo users that is easy to set up and interact with every day. Arlo’s cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. Arlo has recently launched several categories of award-winning connected devices, software, and services. These include wire-free, smart Wi-Fi and LTE-enabled security cameras, video doorbells, floodlights, security system, and Arlo’s subscription services: Arlo Secure and Arlo Safe.

With a mission to bring users peace of mind, Arlo is as passionate about protecting user privacy as it is about safeguarding homes and families. Arlo is committed to implementing industry standards for data protection designed to keep users’ personal information private and in their control. Arlo provides enhanced controls for user data, supports privacy legislation, keeps user data safely secure, and puts security at the forefront of company culture.

NX China Exhibits at 3rd China International Supply Chain Expo (CISCE) in Beijing

TOKYO, Aug. 25, 2025 /PRNewswire/ — Nippon Express (China) Co., Ltd. (hereafter “NX China”), a group company of NIPPON EXPRESS HOLDINGS, INC., participated in the 3rd China International Supply Chain Expo (CISCE) held at the China International Exhibition Center in Beijing, China from Wednesday, July 16 to Sunday, July 20.

Logo: https://drive.google.com/file/d/1dqm0cxpYamnvMUra1AGXMuGlX932Z353/view?usp=drive_link 

Group photo of NX China staff at the CISCE booth: https://drive.google.com/file/d/1uDoYmQl5_2-iNPax8ZuLjxw1YwpL4vJt/view?usp=drive_link 

Organized by the China Council for the Promotion of International Trade (CCPIT), the CISCE is China’s largest exhibition dedicated to the theme of supply chains. Now in its third year, the expo welcomed approximately 650 companies from around 75 countries and regions, with the proportion of overseas exhibitors reaching a record high of 35%. The event concluded successfully, attracting a total of 210,000 visitors, including both industry professionals and the general public.*

*Including online attendees

NX China presented the NX Group’s wide range of logistics solutions, leveraging its strengths as a global logistics company. Its booth highlighted cross-border logistics services as well as international transport solutions utilizing the ChinaEurope railway, which attracted considerable interest from numerous visitors.

The NX Group remains committed to meeting the logistics challenges of its customers and supporting their business expansion with its global network and accumulated expertise in advanced logistics.

About the NX Group: https://drive.google.com/file/d/1mbvBL6C8THZNrR5LREgGeafNkEdaAmV-/view?usp=drive_link 

NX Group official website: https://www.nipponexpress.com/ 

NX Group’s official LinkedIn account: https://www.linkedin.com/company/nippon-express-group/